This brochure provides a detailed overview of our capabilities in schizophrenia model development and preclinical efficacy evaluation, along with representative validated data from rodent models of schizophrenia.

Key highlights covered in this brochure include:

Multiple Schizophrenia Models

We utilize validated schizophrenia models spanning genetic modifications (DISC1, DTNBP1, NRG1) and NMDA receptor hypofunction models (PCP, ketamine, MK-801), each targeting distinct symptom domains and underlying pathological mechanisms.

Comprehensive Case Studies with Key Endpoints

The brochure presents multiple case studies with detailed experimental data:

• MK-801 Models: Spontaneous activity, novel object recognition, and elevated plus maze data demonstrating hyperactivity, cognitive deficits, and anxiety‑like behaviors following MK‑801 administration.
• PCP-Induced Models: Longitudinal study designs with open field, novel object recognition, and prepulse inhibition (PPI) assessments, alongside olanzapine intervention to confirm model predictability.

Advanced Behavioral Testing Platform

Our integrated platform includes a full suite of automated behavioral assays:

• Locomotor & Motor Function: Open field, rotarod, grip strength, treadmill, balance beam, and pole test.
• Cognitive Function: Y-maze, water maze, novel object recognition.
• Social & Emotional Behaviors: Three-chamber social interaction, elevated plus maze, tail suspension, forced swim test.
• Sensorimotor Gating: Prepulse inhibition (PPI) with sound-attenuated chambers.

Multi-Modal Data Integration

In addition to behavioral data, we also provide histological analysis, electroencephalography (EEG) analysis, and imaging analysis. This enables us to correlate behavioral outcomes with neurobiological changes, thereby facilitating deeper mechanistic insights.

This brochure provides an overview of our schizophrenia modeling and preclinical efficacy capabilities, highlighting how Ace Therapeutics supports drug discovery from target validation through safety assessment.

Download the brochure to explore our full schizophrenia modeling capabilities and discover how our integrated platform can accelerate your schizophrenia drug development programs.

You might be interested in...